Takeda set to target EU market with Adcetris following CHMP nod
This article was originally published in Scrip
Executive Summary
Takeda looks set to obtain EU marketing approval for Adcetris (brentuximab vedotin) for the treatment of Hodgkin's lymphoma following a positive opinion from the CHMP.